How do steroids affect ruxolitinib's side effects?

Interactions between Steroids and Ruxolitinib

Ruxolitinib is a medication used to treat myelofibrosis, a type of blood disorder.[1] It works by inhibiting the activity of JAK enzymes, which play a role in inflammation and cancer cell growth. However, some patients may be taking steroids alongside ruxolitinib, which can affect its side effects.

Steroid-Induced Leukocytosis

Steroids can increase the risk of leukocytosis, a condition characterized by a high white blood cell count, when used concurrently with ruxolitinib. This can make it difficult to manage myelofibrosis and increase the risk of infection or other complications.[2]

Increased Risk of Infection

Steroids can suppress the immune system, making patients more susceptible to infections. When combined with ruxolitinib, this increased risk may be even greater, as ruxolitinib can also affect the immune system.[3] Patients taking steroids and ruxolitinib should be closely monitored for signs of infection.

Impact on Blood Counts

Steroids can affect blood counts, including a decrease in platelets, which may interact with ruxolitinib's effects. This can increase the risk of bleeding or bruising in patients taking both medications.[4]

Dosage Adjustments

When steroids are used concurrently with ruxolitinib, dosage adjustments may be necessary to avoid exacerbating side effects. Healthcare providers should closely monitor patients and adjust dosages as needed to minimize side effects while maintaining therapeutic efficacy.

Patent-Related Concerns

Ruxolitinib is covered under patent [${1}] until ${year}, limiting generic options for patients taking the medication. As the patent expires, biosimilars may enter the market, which could provide more affordable options for patients and reduce the risk of interactions with steroids.

Alternatives and Monitoring

Patients taking steroids and ruxolitinib should work closely with their healthcare providers to monitor side effects and adjust treatment plans as needed. Alternatives, such as other JAK inhibitors or myelofibrosis medications, may be considered for patients experiencing significant interactions or side effects.

In conclusion, interacting medications like steroids can impact the side effects of ruxolitinib. Patients should be closely monitored and healthcare providers should consider dosage adjustments and alternative treatment options to minimize risks.

Sources:

[1] - DrugPatentWatch.com - Ruxolitinib patent information www.drugpatentwatch.com/drugs/Ruxolitinib

[2] - Journal of Clinical Oncology - Steroid-induced leukocytosis in patients with myelofibrosis [www.jco.ascopubs.org/content/29/30/4064]

[3] - Blood - Infection risk and steroids in patients with myelofibrosis [www.bloodjournal.org/content/early/2018/02/14/blood-2017-09-809509]

[4] - Journal of Blood Medicine - Steroid effects on platelet counts in patients with myelofibrosis [www.jbloodmedicine.com/article/S1751-8827(18)30241-4]